Hypera Pharma Q2 Net Revenue up 8.5% to 755M BRL EBITDA
Hypera Pharma posted an 8.5% revenue increase and cut net debt to 5.9B BRL, driven by skincare growth and lower financial costs.
Key points
- Net revenue grew 8.5% while EBITDA reached 755 million BRL with a 32.3% margin.
- Net debt was reduced to 5.9 billion BRL, representing 2.1 times EBITDA.
- Hypera approved semaglutide registration and partnered on a non-hormonal menopause treatment.
Hypera Pharma (OTC: HYPMY) reported an 8.5% increase in net revenue for the second quarter of 2026, driven by a 7.6% rise in sell-out volumes. The company attributed this growth primarily to performance in skincare, central nervous system, and gut health categories. New product launches contributed 2.2 percentage points to the sell-out increase, helping Hypera gain market share in target segments that expanded by 6.2%.
Profitability metrics strengthened as gross profit grew 11.5%, outpacing revenue growth by 3 percentage points. This margin expansion resulted in EBITDA of 755 million Brazilian reais, representing a 32.3% margin. Net income rose by 15%, a figure the company linked directly to reduced financial expenses following a capital increase executed in the previous quarter.
Net Debt Reduced to 5.9 Billion Reais
Hypera Pharma successfully lowered its net debt to 5.9 billion reais, equivalent to 2.1 times EBITDA. Management cited strong operating cash flow and efficient working capital management as the primary drivers of this deleveraging. The company noted that internal inventories of raw materials and finished goods were reduced, supporting the overall balance sheet improvement.
Strategic Moves in GLP-1 and Menopause
The firm approved the registration of semaglutide, expanding its presence in the GLP-1 market. Additionally, Hypera announced a partnership to launch a non-hormonal menopausal treatment in Brazil. These initiatives align with the company’s focus on innovation and portfolio expansion, with both products expected to contribute to future growth trajectories.
Marketing Spend Increases Support Brand Visibility
Marketing expenses increased by 13.7% to support brand visibility and the launch of prescription products. According to Benzinga’s coverage of the earnings materials, this spend was aimed at sustaining the momentum in high-growth categories. The gross margin benefit from price increases and input cost control remained a key component of the quarter’s financial performance.
